Inogen Inc
NASDAQ:INGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Inogen Inc
NASDAQ:INGN
|
US |
|
W
|
Winpak Ltd
TSX:WPK
|
CA |
|
P
|
PCC Exol SA
WSE:PCX
|
PL |
|
Everi Holdings Inc
NYSE:EVRI
|
US |
|
Fras Le SA
BOVESPA:FRAS3
|
BR |
|
Broedrene A & O Johansen A/S
CSE:AOJ B
|
DK |
|
J
|
Jiangyin Electrical Alloy Co Ltd
SZSE:300697
|
CN |
|
E
|
Extrawell Pharmaceutical Holdings Ltd
HKEX:858
|
HK |
|
Schaeffler India Ltd
NSE:SCHAEFFLER
|
IN |
|
Glassbridge Enterprises Inc
OTC:GLAE
|
US |
|
Global Fashion Group SA
XETRA:GFG
|
LU |
|
G
|
Gulshan Polyols Ltd
NSE:GULPOLY
|
IN |
|
C
|
Continental Resources Inc
F:C5L
|
US |
|
Greaves Cotton Ltd
NSE:GREAVESCOT
|
IN |
|
Y
|
Yeni Gimat Gayrimenkul Yatirim Ortakligi AS
IST:YGGYO.E
|
TR |
Inogen Inc
Inogen, Inc. engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company is headquartered in Goleta, California and currently employs 1,021 full-time employees. The company went IPO on 2014-02-14. The firm primarily develops, manufactures, and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen with a single battery and can be plugged into a power outlet as needed. All of its Inogen One systems are equipped with Intelligent Delivery Technology, a form of pulse-dose technology, from which the patient receives a bolus of oxygen upon inhalation. The company has also launched Inogen Connect, a wireless connectivity platform for the Inogen One G4 and Inogen One G5 (portable oxygen concentrators) consisting of a front-end mobile application for use by long-term oxygen therapy users and a back-end database portal for use by homecare providers.
Inogen, Inc. engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company is headquartered in Goleta, California and currently employs 1,021 full-time employees. The company went IPO on 2014-02-14. The firm primarily develops, manufactures, and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen with a single battery and can be plugged into a power outlet as needed. All of its Inogen One systems are equipped with Intelligent Delivery Technology, a form of pulse-dose technology, from which the patient receives a bolus of oxygen upon inhalation. The company has also launched Inogen Connect, a wireless connectivity platform for the Inogen One G4 and Inogen One G5 (portable oxygen concentrators) consisting of a front-end mobile application for use by long-term oxygen therapy users and a back-end database portal for use by homecare providers.
Revenue: Inogen reported Q4 revenue of $81.7 million (up 2% YoY) and full year 2025 revenue of $348.7 million (up 4% YoY), meeting its goal for mid-single-digit growth.
Profitability: The company achieved positive adjusted EBITDA of $2.7 million for 2025, its first year of adjusted EBITDA profitability since 2021, and significantly reduced its net loss.
International Growth: International revenue grew 15% YoY in Q4 to $32.5 million, highlighting global expansion as a core growth driver.
Product Diversification: Inogen expanded its portfolio with launches like Voxi 5, Simeox, Aurora CPAP masks, and a digital health portal, broadening its addressable market from $400 million to over $3 billion.
2026 Guidance: Management guided for 6% YoY revenue growth in 2026, to a range of $366–$373 million, and expects continued positive adjusted EBITDA.
Share Repurchase: The board authorized a $30 million share repurchase program to be executed through 2027.
Long-Term Goals: The company aims for high single-digit revenue growth and adjusted EBITDA margin of 10% or more within 3–5 years.
